Share on

Middle East & Africa Atopic Dermatitis Market Research Report – Segmented by Treatment Type, Route of Administration, Distribution Channel & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2023 to 2028)

Published: March, 2023
ID: 5174
Pages: 145
Formats: report pdf report excel report power bi report ppt

Middle East And Africa Atopic Dermatitis Market Size & Growth (2023 to 2028):

The Size of the Atopic Dermatitis Market in the Middle East & Africa is valued at USD 190.98 million in 2023 and is expected to grow at a CAGR of 6.1% to reach USD 256.78 million by 2028 during the forecast period 2023 to 2028.

Atopic dermatitis is an inflammatory skin reaction to many external or internal causes. Internal causes include ingestion of allergic items such as food, medicines, autoimmune disorders, infections, etc., chronic skin disorders, etc. In addition, external factors such as hay fever, dry skin, sweating, extreme hot or cold weather conditions, etc., can aggravate the atopic dermatitis condition leading to eczema and complications. It is mainly seen in younger children and moderately improves with age. According to the American Academy of Dermatology, atopic dermatitis in adults is more resistant to medication than in infants and children. According to a pharmaceutical company report, atopic dermatitis is estimated to affect about 15% to 20% of children worldwide.

In the 2019 Global Burden of Disease Research Database, atopic dermatitis is the leading cause of skin-related disease, affecting up to 25% of the world population, according to JAAD International. In addition, up to 25% of nurses suffer from dermatitis due to regular and frequent hand washing and protective gloves, which makes the skin dry and causes atopic dermatitis. These numbers are predicted to grow with food allergies and seasonal fluctuations, thereby driving the MEA Atopic Dermatitis Market.

Several creams, gels, and medications are prescribed to treat atopic dermatitis; these contain drugs such as steroids, antihistamines, antibiotics, emollients, etc. The growing prevalence of allergies is the main driver for the MEA Atopic Dermatitis Market during the forecast period. Other factors driving this market are the wide range of treatment modalities available in the region, growing focus on research and development, increase in the rate of children, and rising campaigns to generate awareness among people. These factors are said to positively impact the MEA Atopic Dermatitis Market during the analysis duration.

The main factors affecting the MEA market growth are the tough competition between key market players and stringent regulations for product approvals. Furthermore, steroids creams and gels are relatively expensive and are often not covered in the reimbursement policies; this makes it challenging for poor people to afford a long-term supply of the medicines. In addition, the lack of healthcare awareness and infrastructure in the MEA region will hamper the market's growth.

This research report on the Middle East & Africa Atopic Dermatitis Market has been segmented and sub-segmented into the following categories.

By Treatment Type:

  • Drug Treatment
  • Radiation Treatment

By Route of Administration:

  • Topical
  • Oral

By Distribution Channel:

  • Hospital Pharmacies
  • Retail pharmacies
  • online pharmacies

By Country:

  • KSA
  • UAE
  • Israel
  • the rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the Saudi Arabia Atopic Dermatitis Market is anticipated to dominate the MEA atopic dermatitis market throughout the forecast period. The market had a market value of approximately US$ 144 million in the year 2020, trailing a CAGR of 8.3% over the analysis period. This market growth can be accredited to adopting advanced products, harsh weather climate, high prevalence of skin disorders, and greater market penetration.

The UAE Atopic Dermatitis Market will reach a projected market size of US$ 100 million, growing at a CAGR of 4.9%; this is anticipated to be the highest growth rate in the MEA region. Factors such as awareness about atopic dermatitis, easy access to healthcare facilities, and a multicultural population in the region will raise the sales revenues during the projected period. Saudi Arabia and UAE are anticipated to comprise more than half the MEA atopic dermatitis market share.

While the African Atopic Dermatitis Market may not be growing to the growth rate in the Middle East region, the African region will grow at a CAGR of 4.1% and cover nearly 22% of the overall MEA market share. As a result, many international market players are looking into the African region for potential growth opportunities to expand the market over time and meet the unmet market demands.


Key Market Companies dominating the Middle East & Africa Atopic Dermatitis Market Profiled in the Report are Astellas Pharma Inc., Valeant Pharmaceuticals International, Inc., and Sanofi S.A. Other players in the market include Anacor Pharmaceuticals, Inc. Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., and Novartis International AG, Pfizer Inc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample